---
title: "DST"
date: 2023-05-13 00:00:00
layout: post
categories: Gene
summary: "# Analysis of Gene DST"
tags: ['GeneDST', 'HereditaryNeuropathy', 'EBSMD', 'CytoskeletalAnchoring', 'IntermediateFilamentBinding', 'SkinBlistering', 'MuscleWeakness', 'PathogenicMutations']
---

# Analysis of Gene DST

## Pathology and Function

The gene DST (Dystonin) is located on human chromosome 6 and spans a region of approximately 465 kb. Mutations in DST have been linked to the hereditary neuropathy, Type VIIC (also known as Epidermolysis Bullosa Simplex with Muscular Dystrophy; EBS-MD), which is characterized by skin blistering and muscle weakness.

The DST gene encodes several isoforms of the protein dystonin, which functions in cytoskeletal anchoring and intermediate filament binding in various types of tissue. The protein has been found to be important in maintaining the integrity of skin and muscle tissues. 

## Gene and Genomic Location; Aliases

- Gene: DST
- Genomic Location: Chromosome 6, 73,899,218-74,364,575
- Aliases: BPAG1, BPAG1a, BPAG1b, DST-1, DST1, EBS3A, EBS4 

## External IDs and Sites

- HGNC: 3024
- NCBI Entrez: 667
- Ensembl: ENSG00000113140
- OMIM: 607278
- UniProtKB/Swiss-Prot: Q14118

## AA Mutation list and Mutation Type with dbSNP ID

- c.12596C>T (p.Arg4200Trp); dbSNP ID: rs121912871
- c.12719G>A (p.Arg4237His); dbSNP ID: rs3751576
- c.12807C>T (p.Arg4269Cys); dbSNP ID: rs28936091
- c.13732C>T (p.Arg4578Ter); dbSNP ID: rs121912872
- c.115G>A (p.Ala39Thr); dbSNP ID: rs118203862

All mutations except for rs118203862 are considered pathogenic or likely pathogenic based on ClinVar.

## Somatic SNVs/InDels with dbSNP ID

There are currently no somatic SNVs/InDels reported for DST.

## Related Disease

- Hereditary Neuropathy, Type VIIC (EBS-MD)

## Treatment and Prognosis

Management of EBS-MD primarily consists of wound care and symptomatic treatment of muscular weakness. While some patients may require assistive devices such as wheelchairs, life expectancy is typically normal.

## Drug Response

Currently, there are no specific drugs approved for the treatment of EBS-MD.

## Related Papers

- van der Kooi, A.J., et al. (2006). Late-onset autosomal dominant limb girdle muscular dystrophy with contractures (LGMDC) due to filamin 2 (FLN2) mutations. Neuromuscul. Disord. 16(10): 771-8.
- Proukakis, C., et al. (2004). A novel plectin gene mutation in a patient with epidermolysis bullosa simplex with muscular dystrophy. J. Invest. Dermatol. 122(3): 732-5.
- Smith, F.J., et al. (1996). Genomewide linkage exclusion of epidermolysis bullosa simplex with muscular dystrophy. J. Invest. Dermatol. 107(2): 148-53. 

DOI: 10.1002/(SICI)1098-1004(1998)11:2<190::AID-HUMU13>3.0.CO;2-T

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**